| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/25/2014 | CA2376665C Novel tet repressor-based transcriptional regulatory proteins |
| 02/25/2014 | CA2207252C Inhibitors of prenyl transferases |
| 02/20/2014 | WO2014028914A1 Deuterated icotinib derivatives |
| 02/20/2014 | WO2014028665A1 Combination therapies for treating cancer |
| 02/20/2014 | WO2014028653A1 Arsenoplatin anti-cancer agents |
| 02/20/2014 | WO2014028587A1 Compositions comprising chitosan-drug conjugates and methods of making and using the same |
| 02/20/2014 | WO2014028566A1 Combination of pi3k inhibitor and c-met inhibitor |
| 02/20/2014 | WO2014028547A1 Benzodiazepines for treating small cell lung cancer |
| 02/20/2014 | WO2014028543A1 Arry-520 for use in treating cancer in a patient with low aag |
| 02/20/2014 | WO2014028446A1 Anti-jagged anitbodies and methods of use |
| 02/20/2014 | WO2014028381A1 Apoptosis-inducing agents |
| 02/20/2014 | WO2014028081A2 Treatment of hematological neoplasms |
| 02/20/2014 | WO2014028080A1 Treatment of prostate cancer and hematologic neoplasms |
| 02/20/2014 | WO2014028079A1 Treatment of prostate cancer |
| 02/20/2014 | WO2014027996A1 Improved methods for treating cancer with reduced renal toxicity |
| 02/20/2014 | WO2014027994A1 Methods for treatment of cancer using lipoplatin |
| 02/20/2014 | WO2014027959A1 Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
| 02/20/2014 | WO2014027826A1 Butenolide-based compound, preparation method therefor, and pharmaceutical composition containing same |
| 02/20/2014 | WO2014027789A1 Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another |
| 02/20/2014 | WO2014027669A1 Pyrroloquinoline quinone tetraalkali salt, crystals thereof, method for manufacturing same, and composition |
| 02/20/2014 | WO2014027658A1 INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES |
| 02/20/2014 | WO2014027300A1 Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk) |
| 02/20/2014 | WO2014027199A1 Fak and flt3 inhibitors |
| 02/20/2014 | WO2014027078A1 Inhibitor compounds of phosphodiesterase type 10a |
| 02/20/2014 | WO2014027056A1 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| 02/20/2014 | WO2014026997A1 2,3-benzodiazepines |
| 02/20/2014 | WO2014026457A1 Industrial preparation of natural killer cells (nks) and injection using human allogeneic karyocytes |
| 02/20/2014 | WO2014026435A1 Preparation method of targeted graphene nano-drug carrier |
| 02/20/2014 | WO2014026330A1 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| 02/20/2014 | WO2014026286A1 Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| 02/20/2014 | WO2014026282A1 Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors |
| 02/20/2014 | WO2014026277A1 Method for identifying novel minor histocompatibility antigens |
| 02/20/2014 | WO2014026243A1 Vegfr3 inhibitors |
| 02/20/2014 | WO2014026242A1 Vegfr3 inhibitors |
| 02/20/2014 | WO2014002101A8 Lim kinase inhibitors |
| 02/20/2014 | WO2014001956A3 Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment |
| 02/20/2014 | WO2013186726A3 Multicomponent crystals comprising dasatinib and selected cocrystal formers |
| 02/20/2014 | WO2013186630A3 Humanized antibodies to ca215 |
| 02/20/2014 | WO2013149996A9 Substituted tricyclic compounds with activity towards ep1 receptors |
| 02/20/2014 | WO2013133873A3 Pharmaceutical compositions of sodium ion and calcium ion and methods for treating cancer, tumor and non-malignancy |
| 02/20/2014 | US20140051857 Heterocyclic compounds and thrombopoietin receptor activators |
| 02/20/2014 | US20140051759 Bipolar trans carotenoid salts and their uses |
| 02/20/2014 | US20140051631 Pharmaceutical composition comprising tpo or an agonist of the tpo receptor |
| 02/20/2014 | US20140051166 Method and medicament for inhibiting the expression of a given gene |
| 02/20/2014 | US20140050703 Equol-producing lactic acid bacteria-containing composition |
| 02/19/2014 | EP2698637A1 Marker for determination of sensitivity to anti-cancer agent |
| 02/19/2014 | EP2698382A1 Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| 02/19/2014 | EP2698376A1 Cancer-targeting peptides and uses thereof in cancer therapy |
| 02/19/2014 | EP2698372A1 Novel imidazo-oxazine compound or salt thereof |
| 02/19/2014 | EP2698370A2 3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d][1,2,3,5]-tetrazine-8-carboxylic acid amides as anticancer agents |
| 02/19/2014 | EP2698367A1 Benzimidazoles for the treatment of cancer |
| 02/19/2014 | EP2698165A1 Cytotoxic immunoglobulin |
| 02/19/2014 | EP2698156A1 Phenylbutyric acid for chemoprevention |
| 02/19/2014 | EP2698155A1 Pharmaceutical unit dosage form comprising 4-phenylbutyric acid |
| 02/19/2014 | EP2697260A1 Anti- il-1r1 inhibitors for use in cancer |
| 02/19/2014 | EP2697254A2 Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9 |
| 02/19/2014 | EP2697222A1 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent |
| 02/19/2014 | EP2697220A1 Chromenone compounds as pi 3 -kinase inhibitors for the treatment of cancer |
| 02/19/2014 | EP2697219A1 Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists |
| 02/19/2014 | EP2697211A1 Process for preparing docetaxel and its hydrate |
| 02/19/2014 | EP2697208A1 1,3 oxazines as bace1 and/or bace2 inhibitors |
| 02/19/2014 | EP2697205A1 Asymmetrically substituted anthrapyridazone derivatives as cytostatics |
| 02/19/2014 | EP2697199A1 Aryl-or heteroaryl-substituted benzene compounds |
| 02/19/2014 | EP2697198A1 Substituted benzene compounds |
| 02/19/2014 | EP2696898A2 Compositions comprising saccharide binding moieties and methods for targeted therapy |
| 02/19/2014 | EP2696886A2 C1q/tnf-related protein 12 and compositions and methods of using same |
| 02/19/2014 | EP2696881A1 Avian metapneumovirus in oncolysis |
| 02/19/2014 | EP2696878A1 Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
| 02/19/2014 | EP2696858A2 Unit dose form for oral administration |
| 02/19/2014 | CN1980637B Liposomes useful for drug delivery |
| 02/19/2014 | CN103597075A Biologically active nucleotide molecules for selectively killing off cells, use thereof, and application kit |
| 02/19/2014 | CN103597072A Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| 02/19/2014 | CN103596981A Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| 02/19/2014 | CN103596957A Imidazopyridazines as AKT kinase inhibitors |
| 02/19/2014 | CN103596952A Substituted pyridopyrazines as novel Syk inhibitors |
| 02/19/2014 | CN103596948A Chromenone compounds as PI 3-kinase inhibitors for the treatment of cancer |
| 02/19/2014 | CN103596947A 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| 02/19/2014 | CN103596940A Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant |
| 02/19/2014 | CN103596938A 噻唑衍生物 Thiazole derivatives |
| 02/19/2014 | CN103596926A Fused tricyclic compounds as RAF kinase inhibitors |
| 02/19/2014 | CN103596922A Amino lipids, their synthesis and uses thereof |
| 02/19/2014 | CN103596592A Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-ErbB3 agents |
| 02/19/2014 | CN103596581A Adiponectin production promoter, and medicinal composition, food, drink and feed containing adiponectin production promoter |
| 02/19/2014 | CN103596570A Oxidosqualene cyclase as a protein target for anticancer therapeutics |
| 02/19/2014 | CN103589784A Micro-RNA-based method and composition for the diagnosis and treatment of colon cancer-related diseases |
| 02/19/2014 | CN103589754A Herpes simplex virus type 1 carrier system, and preparation method and application thereof |
| 02/19/2014 | CN103589721A Extraction, preparation and application of plant micro ribonucleic acid |
| 02/19/2014 | CN103589568A Compound fermented polygala tenuifolia health wine and production technique thereof |
| 02/19/2014 | CN103589422A Preparation method of fluorescent nanoparticles for suppressing cancer cell |
| 02/19/2014 | CN103588977A Method for extracting and preparing peat fulvic acid and drug application |
| 02/19/2014 | CN103588966A Preparation method of amphiphilic copolymer for targeted photodynamic therapy |
| 02/19/2014 | CN103588891A Preparation method and application of agaricus bisporus polysaccharide with immunocompetence |
| 02/19/2014 | CN103588889A Garcinia oblong ifolia Champ. polysaccharide, its preparation method and application |
| 02/19/2014 | CN103588881A Targeted binding agents directed to PDGFR-alpha and uses thereof |
| 02/19/2014 | CN103588820A Folic acid-nickel coordination polymer nanotube as well as preparation method and application thereof |
| 02/19/2014 | CN103588818A Compound having anticancer activity and preparation method |
| 02/19/2014 | CN103588792A Pyrazolopyrimidine or pyrimidinopyrimidine compounds, preparation method therefor, pharmaceutical compositions thereof and applications thereof |
| 02/19/2014 | CN103588783A Epigambogic alcohol acid, as well as preparation method and medical application thereof |
| 02/19/2014 | CN103588782A Gambogellic acid as well as preparation method and application thereof to medicines |
| 02/19/2014 | CN103588780A Barium cantharidate and preparation method thereof |